Facebook link Linked In link You Tube link

The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases.

Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001 and we look forward to seeing you at our 18th Annual Meeting in San Francisco, California!  



Visit the FOCIS 2018 Annual Meeting microsite to view the program, submit an abstract, register, book a room and more!

Apply to the MMSc Immunology program at Harvard Medical School.

Dedicated Message


News & Information

FOCIS 2018 Registration, Housing and Abstract Submission are Now Open!

FOCIS2018 Nav Button 255x96-01

View the Preliminary Program
Take a look at the innovative lineup of topics and presenters on the FOCIS 2018 preliminary program. Additional presenters and topics will be announced as they are confirmed, so stay tuned!

Submit an Abstract
Submit your science to FOCIS 2018! Share your findings in front of leading clinicians and researchers in immunology. Abstracts are presented during Thematic Symposia, Oral Abstract Sessions, and at the evening Poster Sessions.

Register Now
Register today for THE meeting that will give you a competitive edge in your career. FOCIS registration includes more than 20 scientific sessions with more than 50 top clinicians and researchers from around the globe, speaking on cutting-edge topics across immunology and its related fields.

Book Your Hotel Room
FOCIS 2018 will be held at the San Francisco Marriott Marquis, located downtown in the South of Market (SoMa) neighborhood. Stay where all the action is! FOCIS has negotiated a special rate for FOCIS delegates of $304/night. Discounted trainee rooms are available for $209/night. Book your room today!

See you in San Francisco! #FOCIS

Successful Entrepreneurs in Clinical Academia (ECA) course

focis-eca logo

The Entrepreneurs in Clinical Academia (ECA) 2017 course took place at the INSEAD campus in Fontainebleau, France, on 16-20 October. This is the 5th year in a row that the course has taken place. ECA is an initiative from FOCIS which offers to a small selected group of academic researchers involved in immunology or inflammatory research in Europe the opportunity to discover more about the drug development process and how to get the most out of their research. The course is delivered by INSEAD, one of the best and largest international business schools whose MBA program is ranked the #1 program in the world by the Financial Times. ECA is a free course. All course expenses are covered by FOCIS, thanks to generous support from Celgene. ECA is a powerful and inspiring course during which participants learn what it takes to move a molecule from the laboratory to the market. At the end of the course they understand the importance of obtaining intellectual property, how to assess its economic value, know what data they must generate to satisfy regulators and other stakeholders, the financial resources and skills required to generate these data, and how venture capital companies, biopharmaceutical companies, their university technology transfer office and other parties can help academic entrepreneurs achieve their goals.


All Articles...

FOCIS 2018 Sponsors

 Graphic of 2018 Supporters

 Preview of the latest ePublication

ePub header 2016

May 15, 2017
EDITOR: Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital  EDITORIAL BOARD: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

circlearrow2 Help Not Wanted in the Joint

NEW! The 'Highlights from Recent Literature' review articles are now published monthly on Science Immunology under the "Editor's Choice" article category.


  Reviewed by Andrew H. Lichtman, Brigham and Women's Hospital


Developments in Basic Immunology and Novel Therapies

circlearrow2 Adoptive Cell Therapy with CAR-T cells: Rationale, Promise and Challenges


The idea of treating cancer patients by giving them large numbers of tumor-specific immune cells has been an appealing strategy of cancer immunotherapy for over two decades. The initial approaches relied on isolating rare circulating or tumor-infiltrating T cells (and, in some cases, natural killer [NK] cells) from patients, expanding these cells in culture, and injecting them back into the patients. Such treatments were successful in eliminating tumors in some patients, principally melanoma, but the results have been variable and often disappointing. There are many possible explanations for the modest success of passive immunity conferred by T cells. One important reason may be that in the cell populations used, the frequency of T cells that are specific for the tumor is low, and most of the transferred cells are not doing what it was hoped they would do. In addition, recovery of tumor-specific T cells is higher from certain tumor types such as melanoma, and lower in other tumors, limiting source materials (1).


  Submitted by Abul K. Abbas, MD, and Jonathan H. Esensten, MD, PhD, University of California, San Francisco


Human Immunophenotyping Update

circlearrow2 Sample Saving Technologies and Chip Flow Cytometry

The ever-expanding number of biomarkers, the drive towards precision medicine, the increasing awareness of cellular heterogeneity, and the interest in rare subsets of cells have, in combination, led to a pressing need to be able to perform various assays on sample of limited sizes or of low cellularity. In general, this is being accomplished by performing multiple assays on a single sample (multiplexing) or miniaturizing the technologies and assays, or both.


  Submitted by J. Philip McCoy, Jr., PhD, NHLBI, National Institutes of Health

Selected Recent Clinical Trial Results

circlearrow2 Safety and Tolerability of an ANTI-CD19 MONOCLONAL Antibody, MEDI-551, in Subjects with Systemic Sclerosis: A Phase I, Randomized, Placebo-controlled, Escalating Single-dose Study

Clinical Trial: Schiopu E, Chatterjee S, Hsu V, et al. Arthritis Res Ther. 2016 Jun 07; 18(1):131

Disease: limited or diffuse cutaneous systemic sclerosis (SSc)

Intervention: MEDI-551, an anti-CD19 monoclonal antibody 


  Submitted by Sandra Lord, MD, Benaroya Research Institute. Edited by Carla J. Greenbaum, MD, Benaroya Research Institute